GLP-1 Peptides · SP-028
Tirzepatide
10mg · Lyophilized Powder
Dual GIP/GLP-1 receptor agonist for metabolic and weight management research.
CoA Included
Express Ship
Research Grade
Tirzepatide is a dual GIP and GLP-1 receptor agonist that represents a new class of peptide therapeutics. It is studied for its effects on glucose metabolism, appetite regulation, and body weight management. As a dual incretin agonist, Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
Please Note: Tirzepatide is supplied in lyophilized powder form and must be reconstituted with bacteriostatic water before research use to ensure proper mixing and stability. For research purposes only.
Related Research
The GLP 1 Market in 2026: Trends, Competition, and What Comes Next
The GLP 1 market has exploded into one of the largest pharmaceutical categories in history. This analysis examines the competitive landscape, emerging compounds, and future directions for 2026 and beyond.
Tirzepatide: The Dual GIP and GLP 1 Receptor Agonist Transforming Metabolic Research
Tirzepatide represents a paradigm shift in metabolic research as the first dual GIP and GLP 1 receptor agonist. This article examines the science behind this groundbreaking compound and its implications for metabolic disease research.
Retatrutide: The Triple Agonist Redefining Metabolic Research
Retatrutide takes the incretin concept further than ever before with triple agonism at GIP, GLP 1, and glucagon receptors. Early research data suggests this could be the most potent metabolic compound ever studied.
